Literature DB >> 9395081

Generation and characterization of transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution causing a variant form of Fabry disease.

M Shimmoto1, R Kase, K Itoh, K Utsumi, S Ishii, C Taya, H Yonekawa, H Sakuraba.   

Abstract

Transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution, which was found in a patient with a variant form of Fabry disease, were established. The mice transcribed a sufficient amount of alpha-galactosidase mRNA, but the steady-state levels of the enzyme protein were decreased in liver, kidney and heart, only residual activity being detected in these tissues. The mice will be useful for the clarification of the defective regulation of the structurally altered enzyme protein expressed by the mutant gene at the organ or individual level as well as for the evaluation of drugs that stabilize and/or activate the mutant alpha-galactosidase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395081     DOI: 10.1016/s0014-5793(97)01263-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.

Authors:  Chikara Shiozuka; Atsumi Taguchi; Junichiro Matsuda; Yoko Noguchi; Takanori Kunieda; Kozue Uchio-Yamada; Hidekatsu Yoshioka; Ryoji Hamanaka; Shinji Yano; Shigeo Yokoyama; Kazuaki Mannen; Ashok B Kulkarni; Koichi Furukawa; Satoshi Ishii
Journal:  J Biochem       Date:  2010-10-19       Impact factor: 3.387

2.  Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.

Authors:  Jin-Ok Choi; Mi Hee Lee; Hae-Young Park; Sung-Chul Jung
Journal:  J Biomed Sci       Date:  2010-04-16       Impact factor: 8.410

Review 3.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

4.  Pharmacological chaperone therapy for Fabry disease.

Authors:  Satoshi Ishii
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

5.  Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype.

Authors:  Hassan O A Elsaid; Jessica Furriol; Maria Blomqvist; Mette Diswall; Sabine Leh; Naouel Gharbi; Jan Haug Anonsen; Janka Babickova; Camilla Tøndel; Einar Svarstad; Hans-Peter Marti; Maximilian Krause
Journal:  Mol Genet Metab Rep       Date:  2022-02-17

6.  The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.

Authors:  Richie Khanna; Allan C Powe; Yi Lun; Rebecca Soska; Jessie Feng; Rohini Dhulipala; Michelle Frascella; Anadina Garcia; Lee J Pellegrino; Su Xu; Nastry Brignol; Matthew J Toth; Hung V Do; David J Lockhart; Brandon A Wustman; Kenneth J Valenzano
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.